复方曲尼司特治疗轻、中度支气管哮喘急性发作的疗效分析及对炎症细胞因子的影响  

Efficacy Analysis of Compound Tranilast in the Treatment of Acute Attack of Mild and Moderate Bronchial Asthma and its Effect on Inflammatory Cytokines

作　　者：卢洁 曾崎冈 郑国淑 戴勇 Cytokines LU Jie;ZENG Qi-gang;ZHEN Guo-shu;DAI Yong(Department of Respiratory Medicine,Guangdong Hospital of Integrated Traditional Chinese and Western Medicine,Foshan,Guangdong Province,528200 China)

机构地区：[1]广东省中西医结合医院呼吸内科,广东佛山528200

出　　处：《中外医疗》2020年第5期115-119,共5页China & Foreign Medical Treatment

摘　　要：目的探讨复方曲尼司特治疗轻、中度哮喘患者急性发作的疗效观察及对炎症细胞因子的影响。方法方便选取2017年2-12月于广东省中西医结合医院门诊就诊的轻、中度哮喘急性发作患者共108例,按随机数字法,随机分成沙丁胺醇组、复方曲尼司特组、孟鲁司特钠组,每组各36例,疗程2周,观察3组治疗前后临床疗效、肺功能、FeNO、诱导痰嗜酸性粒细胞百分比、外周血炎症因子等变化情况。结果肺功能方面,复方曲尼司特组、孟鲁司特钠组FEV1[(2.63±0.69)L、(2.61±0.54)L]、FVC [(3.29±0.83)L、(3.27±0.62)L]较沙丁胺醇组FEV1 (2.26±0.78)L、FVC (2.86±0.81)L改善,差异有统计学意义(F=6.802,P=0.033;F=6.828,P=0.033);FeNO下降水平方面,复方曲尼司特组、孟鲁司特钠组[(77.24±8.25)ppb、(76.02±6.98)ppb]下降也显著优于沙丁胺醇组(80.22±20.41)ppb],下降水平(F=12.856,P=0.002);此外,复方曲尼司特组、孟鲁司特钠组在气道高反应性指标如诱导痰嗜酸性粒细胞百分比[(8.99±2.85)%、(8.44±2.43)%]、IgE[(95.10±114.14)IU/mL、(93.61±62.63)IU/mL]水平改善方面也显著优于沙丁胺醇组嗜酸性粒细胞百分比(11.37±1.63)%及IgE(216.43±205.85)IU/mL下降比例(F=15.734,P=0.001;F=6.596,P=0.037)。结论复方曲尼司治疗轻、中度支气管哮喘急性发作疗效可靠,值得临床推广使用。Objective To investigate the clinical effect and influence on inflammatory cytokines in mild and moderate asthma patients treating with compound tranilast. Methods In February 2017 to December 2017 in guangdong province combine traditional Chinese and western medicine hospital outpatient clinic of a total of 108 patients with mild and moderate asthma acute attack, according to the random number method, convenienty divided into groups of salbutamol,compound tranilast group, meng Lu Si sodium group, each group 36 cases, treatment course 2 weeks, observe the three groups before and after treatment clinical curative effect, pulmonary function, Fe NO, induced sputum eosinophil percentage changes, peripheral inflammation factor. Results In terms of lung function, FEV1 [(2.63±0.69)L,(2.61±0.54)L], FVC [(3.29±0.83)L,(3.27±0.62)L] in the compound tranilast group and montelukast sodium group were significantly improved compared with FEV1(2.26±0.78)L and FVC(2.86±0.81)L in the albuterol group PPB(F=6.802, P=0.033;F=6.828, P=0.033);In terms of Fe NO reduction, the decrease of Fe NO in the compound tranilast group and the monteluster sodium group [(77.24±8.25)ppb,(76.02±6.98)ppb] was also significantly better than that in the albuterol group(80.22±20.41)ppb(F=12.856, P=0.002).In addition, the compound tranilast group and the montelukast sodium group were significantly better than the albuterol group in improving the airway hyperreactivity indicators such as the percentage of eosinophil in induced sputum [(8.99 ±2.85)%,(8.44±2.43)%], Ig E[(95.10±114.14)IU/m L,(93.61±62.63)IU/m L and(11.37±1.63)%, Ig E(216.43±205.85)IU/m L(F=15.734, P =0.001;F =6.596, P =0.037). Conclusion Compound tranis is effective in the treatment of mild to moderate bronchial asthma and suitable for clinical application.

关 键 词：轻中度哮喘 复方曲尼司特 肺功能 FENO 炎症因子 

分 类 号：R974[医药卫生—药品]